Regulatoriskt pressmeddelande

Circio Holding ASA – Exercise of Warrants by primary insiders

Oslo, 2 June 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) on 26 May 2026 regarding commencement of the exercise period for warrants from 26 May to 9 June 2026 (the “Exercise Period“).

Certain primary insiders have on the dates stated below, exercised warrants for the allocation of shares:

Ola Melin, Chief Operating Officer of the Company, has on 29 May 2026 exercised a total of 24,241 warrants, for the allocation of 24,241 shares in the Company at a price of NOK 8.2508 per share. Following the delivery of shares from the exercising warrants, Melin will hold 286,007 shares in the Company.

Victor Levitsky, Chief Scientific Officer of the Company, has on 1 June 2026 exercised a total of 30,300 warrants, for the allocation of 30,300 shares in the Company at a price of NOK 8.2508 per share. Following the delivery of shares from the exercising warrants, Levitsky will hold 401,733 shares in the Company.

A total of 67,680,945 warrants were issued on ISIN NO0013711523 in connection with the rights issue and related private placement completed in February 2026 (Nw.: frittstående tegningsretter) (the "Warrants"). Each Warrant gives the holder the right to subscribe for one (1) new share in Circio at the exercise price of NOK 8.2508 per share, during the Exercise Period.

Please see the attached notifications of trade for information regarding the exercise of Warrants by primary insiders of the Company.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.